Enanta Pharma (ENTA) Reports In-Line Q4 EPS

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.22), in-line with the analyst estimate of ($1.22). Revenue for the quarter came in at $23.6 million versus the consensus estimate of $26.34 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance